Time to progression and duration of response. (A-B) Patients who were nonrefractory or refractory to prior bortezomib (A) and by number of prior lines of therapy (B). Median time to progression (11.3 [95% CI, 10.2, –] vs 1.8 [95% CI, 1.2, 4.9] months) and duration of response (10.2 [95% CI, 8.8, –] vs 4.2 [95% CI, 2.3, 8.1] months) were longer for bortezomib-nonrefractory patients than for refractory patients. Median time to progression for patients with 1 to 3 prior lines of therapy was 11.6 months (95% CI, 10.2, –), 4.9 months (95% CI, 1.2, 8.6) for patients with 4 to 6 prior lines of therapy, and 2.1 months (95% CI, 0.7, 5.6) for patients with >6 prior lines of therapy. Median duration of response for patients with 1 to 3 prior lines of therapy was 10.6 months (95% CI, 8.8, –), 7 months (95% CI, 3.5, 15.7) for patients with 4 to 6 prior lines of therapy, and 4.2 months for 1 patient with >6 prior lines of therapy who had a response. Censored events are indicated by a tick mark.